← Evidence map

ArticleWorld journal of urology2008

Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation.

Wengang Cao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

14 papers cite it

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

this papercites it

Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. | OpenQuestion